
Saturday, March 15, 2025 10:00:57 AM
Recent RNAZ News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/16/2025 11:40:11 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2025 08:38:25 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/02/2025 08:58:30 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2025 08:15:44 PM
- TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138 • PR Newswire (US) • 03/27/2025 08:37:00 PM
- TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering • PR Newswire (US) • 03/25/2025 10:24:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2025 12:15:54 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/25/2025 11:00:52 AM
- TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 03/24/2025 03:11:00 AM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 03/20/2025 09:16:50 PM
- TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial • PR Newswire (US) • 03/13/2025 11:47:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2025 09:25:20 PM
- TransCode Therapeutics, Inc. Announces Results of Special Meeting • PR Newswire (US) • 02/25/2025 09:15:00 PM
- TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial • PR Newswire (US) • 02/06/2025 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/04/2025 09:21:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2025 09:20:21 PM
- TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting • PR Newswire (US) • 02/04/2025 09:15:00 PM
- TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial • PR Newswire (US) • 01/14/2025 01:00:00 PM
- Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements • PR Newswire (US) • 01/07/2025 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/30/2024 10:08:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2024 09:10:28 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/19/2024 09:48:14 PM
- TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial • PR Newswire (US) • 12/18/2024 01:00:00 PM
VAYK Corrects Major Clerical Error to Report $668K Operating Revenue for 2024 • VAYK • Apr 17, 2025 9:00 AM
UAV Corp Names David Dugas as President and Chief Operating Officer • UMAV • Apr 17, 2025 8:30 AM
Yuengling's Ice Cream Corporation (OTC: YCRM), Doing Business as ReachOut, Files 2024 10-K With Profitability, Growth, and Corporate Transformation in Focus • YCRM • Apr 16, 2025 11:07 AM
Avant Technologies and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit • AVAI • Apr 16, 2025 8:00 AM
HealthLynked Welcomes Anthony Scuilla as Sales Consultant to Drive Strategic Partnerships with Insurance Providers • HLYK • Apr 14, 2025 8:00 AM
Glidelogic Corp. Partners with Sunwah Global Youth Innovation Center • GDLG • Apr 10, 2025 4:00 PM